&w=3840&q=100)
Biocon Biologics secures multiple market access coverage for Yesintek in US
Biocon Biologics, a subsidiary of Biocon, on Monday said that it has secured multiple market access agreements for Yesintek in the US, its biosimilar which resembles the properties of Stelara.
Clinical trials confirmed that Yesintek demonstrated comparable pharmacokinetics, safety, efficacy, and immunogenicity. A biosimilar is a biological medicine that is highly similar to an already approved biological medicine, also known as the reference product.
Pharmacy benefit management firms like US-based Express Script have added Yesintek to the National Preferred Formulary (NPF) effective March 21. US healthcare multinational Cigna has also added Yesintek to its commercial formulary beginning on March 21.
Yesintek has been approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering patients more affordable options for managing these common chronic autoimmune conditions. It is available in the same formulations as Stelara.
Additionally, Yesintek has been selected as the exclusive Ustekinumab by Blue Cross Blue Shield of Michigan (BCBSM), Florida Healthcare Plan, and several closed-door health systems.
The company is also finalising formulary agreements with other commercial carriers, Biocon said in an exchange filing. The available dosages include 45 mg/0.5 mL prefilled syringe, 90 mg/mL prefilled syringe, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.
The US Food and Drug Administration (FDA) approved Yesintek in December 2024.
'Yesintek represents an important milestone for Biocon Biologics, as this is the first product we have launched in the United States as a fully integrated biosimilars company. The listing of Yesintek on multiple formularies is another validation that payors in the US are committed to broadening access to affordable treatment options,' said Shreehas Tambe, CEO & managing director at Biocon Biologics.
Josh Salsi, head of North America at Biocon Biologics said, over 100 million Americans – representing 70 to 80 per cent of the commercial market – are now covered for Yesintek through commercial formularies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
24 minutes ago
- Time of India
Altimetrik acquires SLK Software
Bengaluru: Digital engineering solutions company Altimetrik is acquiring Bengaluru-based SLK Software to accelerate its goal of reaching $1 billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of this year. Tired of too many ads? go ad free now Financial details were not disclosed. Founded in 2000, SLK Software is a technology services provider focused on bringing AI, intelligent automation, and analytics together to create tech solutions for customers. This strategic acquisition will enhance the scale of Altimetrik's capabilities, bringing together its AI-first, platform-native engineering model and SLK's full technology services stack. This will further accelerate the journey towards modernising enterprise platforms for its customers. Raj Sundaresan, CEO of Altimetrik, stated, "Our investment in SLK reflects our intention to deepen our commitment to customers who are looking for digital, AI-driven solutions that enable business value creation at unparalleled speed and scale." "This is not a traditional integration. It is a strategic acceleration," said Parth Amin, founder and chairman of SLK Software. "In Altimetrik, we've found a partner who shares our values of customer intimacy, people centricity, and a passion for innovation and agility. " Upon the closing of the transaction, the combined entity will serve a global customer base of over 150 businesses, including Fortune 500 companies. Together, the business will employ over 10,000 professionals globally to support customers.
Time of India
27 minutes ago
- Time of India
Welspun bids the most for Lavasa Corporation; Lodha Developers, Jindal Steel and Power Group in fray, too
Lavasa Corporation, India's first private hill town project, is up for sale again. Creditors aim to recover their dues. Six takeover bids have been submitted, ranging from ₹500 crore to ₹850 crore. Welspun Group placed the highest bid. Other bidders include Ashdan, Pride Purple, Macrotech Developers, DB Corp subsidiary Valor, Jindal Steel and Power Group, and Yogayatan Group. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: Lavasa Corporation , once touted as India's first private hill town project, has received six takeover bids-ranging from ₹500 crore to ₹850 crore-as creditors try to sell the debt-laden entity for a second time to recover their dues. The Welspun Group , through a subsidiary, placed the highest bid of ₹850 crore, including ₹150 crore of process costs, documents accessed by ET bidders include Pune-based developers Ashdan and Pride Purple, Macrotech Developers (now Lodha Developers), DB Corp subsidiary Valor, Jindal Steel and Power Group, and Mumbai-based Yogayatan Group. Details accessed by ET show that Ashdan and Pride Purple have placed a combined bid aggregating to ₹843 crore. The payment timelines for the bids are five to nine be sure, most of the bids are conditional to the project receiving environmental clearance from the Maharashtra government-the primary reason it slipped into distress."Only Yogayatan has no preconditions on environmental clearance," a person aware of the details told ET. "Its bid at around ₹800 crore is also strong. Remains to be seen if lenders want to negotiate more."Another person in the know said conditional bids are unacceptable under the National Company Law Tribunal 's debt resolution process. "The committee of creditors (CoC) will have to meet and seek an alternative," the person sent to EY-backed resolution professional Udayraj Patwardhan and process advisor to lender BoB Capital Markets did not elicit any response. Lenders are grappling with litigations on this distressed debt as they try to find a buyer for a second time after junking the previous attempt last year. Even at ₹850 crore, the highest bid received, the total recovery is less than 13% of dues of over ₹6,642 crore, after more than seven years of NCLT had in July 2023 approved a resolution proposal from Darwin Platform Infrastructure (DPIL) submitted in December 2021, offering total payout of ₹1,814 crore to lenders over eight years and promising to deliver fully constructed houses to 837 Mumbai bench of NCLT called off the resolution plan after a full year of hearing in September last year, noting that DPIL failed to make the ₹100-crore upfront payment without any justifiable reasons. Tribunal allowed revival of resolution process and let CoC to exclude the period from July 13, 2021, to January 3, 2022, from resolution process. Lavasa was promoted as India's first privately built and managed city at the turn of the century, targeting rich urban natives from Mumbai and Pune wanting to escape the noise and pollution of cities.
Time of India
27 minutes ago
- Time of India
India, US push for trade pact as deadline nears
India and the US are engaged in intense trade negotiations to finalize a pact before the July 9 deadline, addressing contentious issues like tariffs and market access. While progress has been made, disagreements persist on matters such as patent laws and agricultural imports. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Hectic discussions are ongoing between India and the US to clinch a trade pact ahead of the July 9 deadline when the 90-day pause period for Washington's retaliatory tariffs comes to an and American trade negotiators have managed to find closure on many issues, and Indian trade officials have extended their visit to the US to conclude the talks."Both sides were clear in this round and not yielding on certain issues but have achieved closure on many grounds," said a person aware of the Delhi has stated that section 3(d) of the Indian Patents Act is non-negotiable and will not be reviewed. The section prohibits the grant of 'evergreening' patents, which are additional patents for a drug with no therapeutic benefit and are seen to increase the term of a patent wants the entire 26% tariff to be rolled back whereas the US wants to sell genetically modified crops to India, a sensitive area for New and dairy sectors are "difficult and challenging areas for India. And India has not opened up dairy in any of its free trade pacts," said the last round of talks would discuss both the interim and first tranche of the bilateral trade agreement (BTA) which is aimed to be concluded by week, US President Donald Trump said a big trade deal may be coming up with India and asserted that the US would "open up" the Trump administration had also indicated that the July 9 deadline could be extended but the final decision rests with the the deadline is not extended, the tariffs would come to the April 2 level of 26% in the case of it is not extended, India may gain in some areas and lose in some others compared to other countries, but the US will also get affected because of the high tariffs, another official had said experts expect a limited trade pact similar to the US-UK mini trade deal where India could cut tariffs on automobiles along with a limited market access through tariff reductions and tariff-rate quotas on American ethanol, almonds, walnuts, apples, raisins, avocados, olive oil, spirits and wine."This would leave out the broader free trade agreement issues such as services trade, intellectual property rights, and digital regulations for future negotiations," said a Delhi-based trade expert.
